Novartis' recent Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) demonstrated that a certain antibody reduced mortality due to lung cancer by 77 percent, according to a news release.
During the study, researchers saw a 67 percent reduction of lung cancer case in those involved. People involved in the study took a placebo, a 50-milligram shot of ACZ885, a 150-milligram shot of ACZ885 or a 300-milligram shot of ACZ885 every three months. Scientists saw a reduced mortality rate due to lung cancer in those who received the 300-milligram shot.
In the Phase III test, researchers determined how ACZ885 affects people who have had a heart attack and have inflammatory atherosclerosis as measured by high-sensitivity C-reactive protein (hsCRP). People who have hsCRP readings right at or higher than 2 milligrams per liter and those who have not previously had cancer took part in the test.
The CANTOS study included over 10,000 people over the past six years, placing it among the biggest and continuous trial Novartis has conducted.